BDP Week 03/30/2015 - 04/02/2015 Huntington Beach, CA
LONG® EGF is a recombinant analogue of human epidermal growth factor (EGF) already used in regulatory approved cell-based therapies. Developed as a supplement for use in therapeutic cell culture applications as a like-for-like replacement for native EGF or recombinant human EGF (hEGF), it comprises the human EGF amino acid sequence plus a 53 amino acid N-terminal extension peptide.
LONG® EGF is used across a wide range of customer-driven applications, including:
- Therapeutic cell culture in a variety of fibroblast and epithelial cell types
- Keratinocyte differentiation and growth
- Cell-based vaccine production
LONG® EGF can be used as a supplement for serum-free or low serum culture. It is also suitable for animal growth studies, general research and further manufacturing applications. Recombinant LONG EGF acts via the Erb-1 receptor and has applications in fibroblast cell culture. Synergistic effects have been observed with LONG®R3IGF-I in HEK293, PER.C6®, MDCK and HeLa cell lines. LONG EGF has also shown synergistic effect with LONG®TGF-α in keratinocyte differentiation and growth.
A proprietary Escherichia coli fermentation process, manufactured without the use of animal- or human-derived materials.